MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
Agios Pharmaceuticals EBITDA 2011-2026 | AGIO
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Agios Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -467 M | -420 M | -385 M | -381 M | -370 M | -327 M | -418 M | -355 M | -314 M | -195 M | -115 M | -52.8 M | -37.4 M | -21.8 M | -15.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -15.8 M | -467 M | -258 M |
Quarterly EBITDA Agios Pharmaceuticals
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | -91.1 M | -97.6 M | -101 M | - | -91.2 M | -91.2 M | -91.2 M | -92.4 M | -80.3 M | -83.3 M | -84.6 M | -106 M | -109 M | -110 M | -95.5 M | -96.4 M | -93.9 M | -69.5 M | -92.3 M | -90.1 M | -74.2 M | -81.4 M | -65.5 M | -57.4 M | -59.5 M | -53.9 M | -22.3 M | -40.9 M | -38.3 M | -31 M | -4.82 M | -26.7 M | 4.21 M | -17.7 M | -12 M | -12.2 M | -9.97 M | -7.8 M | -6.7 M | -6.5 M | -4.25 M | -5.59 M | -5.26 M | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.21 M | -110 M | -57.3 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Altimmune
ALT
|
-94.4 M | $ 3.41 | 2.1 % | $ 300 M |  USA |
 |
Amgen
AMGN
|
14.2 B | $ 350.17 | 0.68 % | $ 188 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
172 M | $ 19.57 | 0.36 % | $ 915 M | USA |
 |
I-Mab
IMAB
|
13.8 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.11 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
-452 M | $ 217.82 | -1.83 % | $ 5 B |  Danmark |
 |
Autolus Therapeutics plc
AUTL
|
-234 M | $ 1.4 | 1.82 % | $ 357 M |  Britain |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.18 M | - | -1.52 % | $ 24.7 M | USA |
 |
Aytu BioScience
AYTU
|
-2.45 M | $ 2.64 | 1.15 % | $ 16.6 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-16.2 M | - | - | $ 26.5 M | USA |
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-9.76 M | - | -10.17 % | $ 12.2 K | USA |
 |
Benitec Biopharma
BNTC
|
-9.77 M | $ 11.0 | 0.18 % | $ 453 M | USA |
 |
Acorda Therapeutics
ACOR
|
-233 M | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
-65 M | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
220 M | - | - | - |  Russia |
 |
Avenue Therapeutics
ATXI
|
-11.3 M | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-136 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-24.5 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-35.9 M | - | -9.65 % | $ 45.9 M | USA |
 |
Coherus BioSciences
CHRS
|
-180 M | $ 1.58 | 3.62 % | $ 185 M | USA |
 |
Cellectis S.A.
CLLS
|
-131 M | $ 3.35 | 0.3 % | $ 116 M | France |
 |
Ayala Pharmaceuticals
AYLA
|
-37.3 M | - | - | $ 7.46 M |  Israel |
 |
Cullinan Management
CGEM
|
-241 M | $ 12.83 | 0.71 % | $ 773 M | USA |
 |
Atreca
BCEL
|
5.46 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
37.3 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
589 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Calithera Biosciences
CALA
|
-115 M | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
-121 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
-127 M | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
-22.4 M | - | -74.18 % | $ 955 K | USA |
 |
CorMedix
CRMD
|
151 M | $ 6.29 | 0.64 % | $ 453 K | USA |
 |
CytomX Therapeutics
CTMX
|
-21.2 M | $ 4.41 | -1.01 % | $ 608 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
-56.2 M | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
-217 M | - | -7.23 % | $ 13 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-242 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Compugen Ltd.
CGEN
|
-34.6 M | $ 2.12 | 1.2 % | $ 198 M | Israel |
 |
Denali Therapeutics
DNLI
|
-480 M | $ 20.92 | 3.69 % | $ 3.44 B | USA |
 |
Dyadic International
DYAI
|
-8.23 M | $ 0.89 | -5.85 % | $ 25.6 M | USA |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-76.7 M | $ 4.26 | 0.47 % | $ 707 M | Canada |
 |
Akouos
AKUS
|
-84.3 M | - | 0.23 % | $ 488 M | USA |